Keywords: vertex, vx-702, enters, ph, ii, cambridge, massachussets
Vertex' VX-702 enters Ph II
Article | 20 June 2005
Cambridge, Massachussets, USA-headquartered Vertex Pharmaceuticals has initiated dosing in a Phase II clinical study in rheumatoid arthritis with VX-702, an ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
